Tetra Bio-Pharma Inc. (OTCQB:TBPMF) (TSX:TBP) (FRA: JAM1), signed an agreement with Cellvera Global Holdings LLC, for the co-development of ARDS-003 as a combination product, with Qifenda 400mg (Favipiravir), a commercial-stage broad-spectrum antiviral drug.
As a monotherapy, compared to placebo, ARDS-003 dose-dependently reduced signs of morbidity and mortality, including respiratory distress following SARS-CoV-2 infection in the humanized ACE2 mouse model. ARDS-003 also outperformed an antiviral drug in reducing multiple proinflammatory mediators involved in hyperinflammation and immune system dysfunction following viral infection. Other studies have also demonstrated dose-dependent inhibition of viral replication.
